Clinical Trial Update: A Single-arm Phase 2 Prospective Clinical Study of Enatumab in the Treatment of Relapsed/Refractory Warm Antibody Autoimmune Hemolytic Anemia [Phase 2]

View source ↗

Summary

Phase 2 single-arm trial of enatumab for relapsed/refractory warm antibody autoimmune hemolytic anemia; not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autoimmune Hemolytic Anemia

Drugs mentioned

• Enatumab (Enatumab)

Snippet

Sponsor: Bing Han | Conditions: Autoimmune Hemolytic Anemia | Phase 2 | Status: NOT_YET_RECRUITING